Best Supermarket Stocks To Watch For 2015

LONDON -- You won't need telling that these are tough times for Tesco (LSE: TSCO  ) (NASDAQOTH: TSCDY  ) . The big cheese of British supermarkets has found itself in one pickle after another, serving up the U.S. Fresh & Easy debacle, its first profit warning for 20 years, a 25% share price drop, and a dollop of minced horsemeat. It has even been shrinking in Asia, with sales dropping 3.8% in the first quarter, on top of a 1% fall in U.K. sales. Chief executive Philip Clarke has given up the fight to sell electronics, abandoning the field to online giant Amazon.

Then take a look at J Sainsbury (LSE: SBRY  ) (NASDAQOTH: JSAIY  ) . It has just reported its 34th consecutive quarter of like-for-like growth. Total sales for the first quarter rose 3.6%. Like-for-like sales rose 0.8%, excluding food. And while Tesco dumps electrics, nonfood sales at Sainsbury's are growing at twice the rate as food, notably in cookware, homeware, and -- ahem -- kitchen electricals. You really can taste the difference.

Best Supermarket Stocks To Watch For 2015: KBB Resources Bhd (KBB)

KBB Resources Berhad is an investment holding company. The Company is engaged in manufacturing and marketing of all types of rice and sago sticks (vermicelli), sago starch and related products. The Company�� product includes Rice Vermicelli, Instant Noodle, Instant Bihun, Laksa and Sago. The Company�� subsidiaries include Kilang Bihun Bersatu Sdn Bhd, which is engaged in Manufacturing and marketing of all types of rice and sago sticks (vermicelli); Rasayang Food Industries Sdn Bhd, which is engaged in manufacturing and trading of beehoon and beehoon laksa; Bersatu Noodles Industries Sdn Bhd, which is engaged in manufacturing and trading of noodles and related products, and Bersatu Biotechnology (Johore) Sdn Bhd, which is engaged in manufacturing and marketing of all types of sago starch and related products. Advisors' Opinion:

• [By Neha Marwah]

  LMC Automotive expects the annualized rate to be 16.1 million, the best in six years. This is a decent improvement from last year�� November, when the industry reported 15.3 million as the adjusted annualized rate. In comparison, Kelley Blue Book (KBB) expects the November 2013 SAAR to be around 15.6 million, while Edmunds.com estimates it to be 15.7 million.

Best Supermarket Stocks To Watch For 2015: Cancer Genetics Inc (CGIX)

Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.

The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.

CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.

Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA

MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).

MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.

The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.

During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.

Urogenital cancer arrays: UroGenRA, UGenRA

The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.

UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.

UGenRA for Endometrial, Ovarian and Cervical Cancers

UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.

UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.

Advisors' Opinion:

• [By Lauren Pollock]

  Biopharmaceutical development company CytRx Corp.(CYTR) and early-stage diagnostics company Cancer Genetics Inc.(CGIX) separately disclosed plans to sell stock. CytRx, whose offering of 10 million shares priced at an 18% discount, is aiming to raise money to fund its clinical trials, while Cancer Genetics wants to hire more sales and marketing personnel, as well as fund research and development. CytRx dropped, while Cancer Genetics fell.

Best Oil Companies For 2015: Solitron Devices Inc (SODI)

Solitron Devices, Inc., incorporated on March 12, 1987, designs, develops, manufactures and markets solid-state semiconductor components and related devices primarily for the military and aerospace markets. The Company manufactures a variety of bipolar and metal oxide semiconductor (MOS) power transistors, power and controls hybrids, junction and power MOS field effect transistors (Power MOSFETS), field effect transistors and other related products. It's products are custom made pursuant to contracts with customers whose end products are sold to the United States government. The Company�� semiconductor products can be classified as active electronic components. The Company�� active electronic components include bipolar transistors and MOS transistors.

The Company�� semiconductor products are used as components of military, commercial, and aerospace electronic equipment, such as ground and airborne radar systems, power distribution systems, missiles, missile control systems, and spacecraft. Its products have been used on the space shuttle and on the spacecraft sent to the moon, to Jupiter (on Galileo) and, to Mars (on Global Surveyor and Mars Sojourner).

Power Transistors

The Company manufactures a variety of power bipolar transistors for applications requiring currents in the range of 0.1 ampere to 300 ampere or voltages in the range of 30 volts to 1000 volts. It also manufactures power diodes under the same military specification. In addition, it manufactures power N-Channel and P-Channel MOSFET transistors and is expanding that line in accordance with customers��requirements.

Hybrids

The Company manufactures thick film hybrids, which generally contain discrete semiconductor chips, integrated circuits, chip capacitors and thick film or thin film resistors. The hybrids are of the high-power type and are custom manufactured for military and aerospace systems. Some of the Company�� hybrids include high power voltage regulators, p! ower amplifiers, power drivers, boosters and controllers. The Company manufactures both standard and custom hybrids.

Voltage Regulators

Voltage regulators provide the power required to activate electronic components such as the integrated circuits. These circuits are found in all electronic devices from radar and missile systems to smart phones.

Field Effect Transistors

The Company manufactures about 30 different types of junction and MOS field effect transistor chips. They are used to produce over 350 different field effect transistor types. The Company�� field effect transistors conform to standard Joint Electronic Device Engineering Council designated transistors, commonly referred to as standard 2N number types. It manufactures both standard and custom field effect transistors.

The Competes with IXYS Corporation, Motorola Inc., International Rectifier, Microsemi Corporation, M.S. Kennedy Corporation, Natel Engineering Company and Sensitron Semiconductor.

Advisors' Opinion:

• [By Geoff Gannon] strong>OPT-Sciences (OPST)

  Micropac

  Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.

  ADDvantage

  ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.

  By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.

  That�� pretty typical in the world of net-nets.

  Solitron

  Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO ��we��e still talking about a company where one person has a lot of control. Solitron only has three directors. Saraf is the chairman, CEO, president, CFO and treasurer. Neither of the other two directors joined the board within the last 15 years. So, we aren�� talking about a lot of tumult at the top.

  In fact, profitable net-nets seem to be especially common candidates for abandoning the responsibilities of a public company without actually getting taken private.

  OPT-Sciences

  This

• [By Geoff Gannon]

  Solitron (SODI) sells at 74% of NCAV, has decent z- and f-scores, a FCF margin of 5.3% and an ROA of 12%.
  
  Micropac (MPAD) sells at 83% of NCAV, has similar (slightly better) z- and f-scores, a FCF margin of 6%, but has ROA of 28%.
  
  ADDvantage (AEY) sells at 95% of NCAV, has similar (in the ballpark) scores and FCF and ROA of 23%.

• [By Geoff Gannon] on the amount of stock you can buy and the position size you like. For me, I try not to start buying a stock that I think will never make up 10% of my portfolio. If you don�� mind having 5% positions in your portfolio, your portfolio can obviously be twice as big as mine and you can still consider buying the same small stocks I do. In terms of specific stocks, it depends on the amount of float and the volume the stock trades in an average month. We are really getting into specifics here. And I may be boring people. But if you�� like to hear more about the minutiae of how you actually buy and sell tiny stocks like these, let me know, and I��l do an article on the subject.

  By the way, there is a hard and fast rule of thumb that it usually makes no sense to invest in a company with a market cap that is smaller than your portfolio. This is true for both fund and individual investors. Funds break it all the time. But, frankly, it is probably a waste of an analyst/fund manager�� time to even analyze such tiny positions relative to the size of the whole portfolio. Since even when we are discussing very small stocks we are still talking about millions and millions of dollars in market cap, this is hardly a concern for most individuals.

  So, for individual investors, actual inability to acquire enough shares of a company to meaningful influence their portfolio is rarely the problem. If you bid for a stock month after month ��you��l get your shares.

  The concern for individual investors is not whether buying enough shares is possible. The concern is how quickly and easily you can buy and sell. This is what we call ��iquidity.��/p>

  Instead of thinking about stocks as liquid or illiquid, you should think in terms of your portfolio and your liquidity needs. It doesn't make much sense to use what I'll call an "objective" (as in stock-oriented) approach to liquidity rather than a "subjective" (as in investor-oriented) approach to liquidity.

  <

Best Supermarket Stocks To Watch For 2015: Marriott International Inc (MAR)

Marriott International, Inc., incorporated on September 19, 1997, is a diversified hospitality company. It is a lodging company with more than 3,700 properties in 73 countries and territories. It operates in four business segments: North American Full-Service Lodging, which includes the Marriott Hotels & Resorts, Marriott Conference Centers, JW Marriott, Renaissance Hotels, Renaissance ClubSport, and Autograph Collection properties located in the United States and Canada; North American Limited-Service Lodging, which includes the Courtyard, Fairfield Inn & Suites, SpringHill Suites, Residence Inn, TownePlace Suites, and Marriott ExecuStay properties located in the United States and Canada; International Lodging, which includes the Marriott Hotels & Resorts, JW Marriott, Renaissance Hotels, Autograph Collection, Courtyard, AC Hotels by Marriott, Fairfield Inn & Suites, Residence Inn, and Marriott Executive Apartments properties located outside the United States and Canada, and Luxury Lodging, which includes The Ritz-Carlton, Bulgari Hotels & Resorts, and EDITION properties worldwide (together with residential properties associated with some Ritz-Carlton hotels). In January 2014, the Company announced that it has sold its leasehold interests in the Renaissance Barcelona Hotel to an affiliate of the Qatar Armed Forces Investment Portfolio (QAFIP).

On November 21, 2011 (the spin-off date), the Company completed a spin-off of its timeshare operations and timeshare development business. Under license agreements with the Company, Marriott Vacations Worldwide Corporation (MVW) is the developer and operator of timeshare, fractional, and related products under the Marriott brand and the developer of fractional and related products under The Ritz-Carlton brand. The Company receives license fees under these licensing agreements. In April 2012, it opened the Renaissance Barcelona Hotel. In September 2012, its JW Marriott hotel brand has opened JW Marriott Essex House New York in New York City.

The Company is a worldwide operator, franchisor, and licensor of hotels, corporate housing properties, and timeshare properties under a number of brand names. The Company also operates, markets, and develops residential properties and provides services to home/condominium owner associations. As of December 31, 2011, the Company operated, franchised or licensed 3,718 lodging properties worldwide, with 643,196 rooms inclusive of 32 home and condominium products (3,838 units) for which it manages the related owners��associations. As of December 31, 2011, the Company provided 2,166 furnished corporate housing rental units. As of December 31, 2010, it operated 1,104 properties (284,868 rooms) under long-term management agreements with property owners, 45 properties (10,957 rooms) under long-term lease agreements with property owners, and five properties (986 rooms) as owned. During the year ended December 31, 2010, the Company bought one land parcel for hotel development and one hotel, and sold two limited-service properties, one full-service property and one land parcel. As of December 31, 2011, the Company had 24671 franchised properties (332,636 rooms), 85 unconsolidated joint venture properties (8,721 rooms), and 64 timeshare, fractional and related properties (12,800 units).

North American Full-Service Segment, North American Limited-Service Segment, International Segment Lodging Products

Marriott Hotels & Resorts is the Company�� global flagship brand, serving business and leisure upper-upscale travelers and meeting groups. Marriott Hotels & Resorts properties are located in downtown, urban, and suburban areas, near airports, and at resort locations. As of December 31, 2011, there were 492 Marriott Hotels & Resorts properties (178,854 rooms), excluding JW Marriott and Marriott Conference Centers. As of December 31, 2011, there were 10 Marriott Conference Centers (2,915 rooms) throughout the United States. JW Marriott is a global luxury brand made up of a collection o! f propert! ies and resorts. As of December 31, 2011, there were 53 properties (23,826 rooms) primarily located in gateway cities and upscale locations globally. Renaissance Hotels properties are located in downtown locations of major cities, in suburban office parks, near gateway airports, and in destination resorts. As of December 31, 2011, there were 154 Renaissance Hotels properties (52,966 rooms), including two Renaissance ClubSport properties (349 rooms).

The Autograph Collection consists of upper-upscale and luxury, independent hotels located in major cites. As of December 31, 2011, there were 27 Autograph Collection properties (6,105 rooms) operating in the United States.

During the year ended December 31, 2011, the Company entered into joint ventures with AC Hotels of Spain to create the AC Hotels by Marriott co-brand. AC Hotels typically contain 50 to 150 rooms and are located in destination, downtown, and suburban markets. As of December 31, 2011, there were 80 AC Hotels by Marriott properties (8,371 rooms) in Spain, Italy, and Portugal. Courtyard is the Company�� select-service hotel product for the upper-moderate price tier. The hotels typically contain 90 to 150 rooms in suburban locales and 140 to 340 rooms in downtown domestic and international locales. As of December 31, 2011, there were 913 Courtyards (134,719 rooms) operating in 37 countries and territories.

Fairfield Inn & Suites offers a range of amenities, including free in-room high-speed Internet access and free wireless fidelity (Wi-Fi) access in the lobby, on-site business services (copying, faxing, and printing), a business center/lobby computer with Internet access and print capability, continental breakfast buffet, The Market, exercise facilities, and a swimming pool. In addition, suite rooms provide guests with separate areas for sleeping, working, and relaxing, as well as in-room amenities, including a microwave and refrigerator. As of December 31, 2011, there were 431 Fairfield Inn & Suites propert! ies and 2! 49 Fairfield Inn properties operating in the United States, Canada, and Mexico. SpringHill Suites properties typically have 90 to 165 suites. The brand offers a broad range of amenities, including free in-room high-speed Internet access and free Wi-Fi access in the lobby, The Market (a self-serve food store open 24 hours a day), complimentary hot breakfast buffet, lobby computer and on-site business services (copying, faxing, and printing), exercise facilities, and a swimming pool. As of December 31, 2011, there were 285 properties (33,466 rooms) located in the United States and 2 properties (299 rooms) in Canada.

Residence Inn is North America�� hotel brand designed for business and leisure travelers staying five or more nights. As of December 31, 2011, there were 617 Residence Inn properties (74,867 rooms) located in the United States, Canada, Costa Rica, United Kingdom, and Germany. As of December 31, 2011, 193 TownePlace Suites properties (20,048 rooms) were located in 42 states. Marriott ExecuStay provides furnished corporate apartments for long-term stays nationwide. As of December 31, 2011, Marriott leased approximately 2,200 apartments and its 11 franchisees leased approximately 2,500 apartments. Apartments are located in 43 different markets in the United States, of which 34 are franchised. Marriott Executive Apartments provides temporary housing for business executives and others who need accommodations outside their home country, usually for 30 or more days. As of December 31, 2011, 20 Marriott Executive Apartments and two other Serviced Apartments properties (3,700 rooms total) were located in 16 countries and territories. All Marriott Executive Apartments are located outside the United States.

Luxury Segment Lodging Products

The Ritz-Carlton is a global luxury lifestyle brand, which consists of hotels and resorts. The Ritz-Carlton properties include spa and wellness facilities, restaurants, championship golf courses, and The Ritz-Carlton Club Level! . Through! a joint venture with jeweler and luxury goods designer Bulgari SpA, the Company operates the luxury hotel properties in prime locations under the name Bulgari Hotels & Resorts. As of December 31, 2011, it operated the Bulgari Milano Hotel (58 rooms), in Milan, Italy, and the Bulgari Bali Resort, which features 59 private villas, two restaurants, and comprehensive spa facilities. It also operates two restaurants in Tokyo, Japan, which are co-located with two Bulgari retail stores. The EDITION brand offers a lodging experience on a global scale.

Advisors' Opinion:

• [By Jesse Solomon]

  Investors have taken notice. Marriott International (MAR)has soared 33% this year while Hyatt (H) is up 26%. Hilton (HLT) has spiked roughly 23% from its initial public offering in December.

• [By John Udovich]

  Small cap hotel stock La Quinta Holdings Inc (NYSE: LQ) just had its IPO to raise a lower than expected $650 million after being priced below its expected range, meaning its worth taking a closer look at the stock which�is focused on the�mid-priced hotel market along with the performance of potential benchmarks like hotel stocks Marriott International Inc (NASDAQ: MAR), Choice Hotels International Inc (NYSE: CHH) and Wyndham Worldwide Corporation (NYSE: WYN).

Best Supermarket Stocks To Watch For 2015: Tesco Corporation(TESO)

Tesco Corporation engages in the design, manufacture, and service delivery of technology based solutions for the upstream energy industry worldwide. The company?s Top Drive segment manufactures, sells, and supports top drives used in drilling operations to rotate the drill string while suspended from the derrick above the rig floor. This segment?s product line includes various portable and permanently installed top drive products with lifting capacities of 150 through 750 tons, which are hydraulically and electrically powered. It also provides top drive rental services on a day-rate basis for land and offshore drilling rigs and engages in the recertification of working units, such as top drives, power units, and other top drive product and component repairs. This segment serves drilling contractors, rig builders, equipment brokers, and oil and natural gas operating companies. Its Tubular Services segment offers proprietary tubular services using its Casing Drive System, a tool that facilitates running and reaming casing into a well bore; and installation service of deep water smart well completion equipment using the company?s Multiple Control Line Running System technology. This segment also provides equipment and personnel for the installation of tubing and casing, including power tongs, pick-up/lay-down units, torque monitoring services, connection testing services, and power swivels for new well construction, and in work-over and re-entry operations. The company?s CASING DRILLING segment provides CASING DRILLING technology, which allows an oil or gas well to be drilled using well casing pipe, eliminating the use of drill pipe and drill collars. Tesco Corporation was founded in 1986 and is headquartered in Houston, Texas.

Advisors' Opinion:

• [By Garrett Cook]

  In trading on Friday, energy shares were relative laggards, down on the day by about 0.40 percent. Top losers in the sector included Callon Petroleum Company (NYSE: CPE), down 5 percent, and Tesco (NASDAQ: TESO), off 3.9 percent.

• [By Sophia Yan]

  Wal-Mart (WMT, Fortune 500) said this month that it would close a number of stores in China. Earlier this year, Tesco (TESO) transferred its 131 stores and shopping mall business in China to a joint venture with a state-owned company.

Best Supermarket Stocks To Watch For 2015: Etfs Gold Trust (SGOL)

ETFS Gold Trust (the Trust) is an investment trust. The investment objective of the Trust is for the Shares to reflect the performance of the price of gold bullion, less the expenses of the Trust�� operations. The Trust holds gold bullion and issues ETFS Physical Swiss Gold Shares (the Shares) in exchange for deposits of gold and distributes gold in connection with redemption of Baskets. The sponsor of the Trust is ETF Securities USA LLC (the Sponsor). The trustee of the Trust is The Bank of New York Mellon and the custodian is JP Morgan Chase Bank N.A. Advisors' Opinion:

• [By Peter Pham]

  Although the Fed doubled its bond buying last September, the top gold exchange-traded funds, or ETFs, including SPDR Gold Shares (NYSEMKT: GLD  ) , iShares Gold Trust (NYSEMKT: IAU  ) , and ETFS Physical Swiss Gold Shares (NYSEMKT: SGOL  ) , have dropped around 25% each over the last 12 months, which speaks to gold's extreme vulnerability to QE tapering. Even the mere mention of tapering seems to send gold into a tailspin, as seen with SPDR Gold Shares, which has plunged 24% year to date and also suffered massive losses with its physical holdings. Market Vectors Gold Miners ETF (NYSEMKT: GDX  ) has suffered a massive drop of 48% so far in 2013, making it one of the worst-performing ETFs this year.